相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies
Cristina Varas-Lorenzo et al.
BMC CARDIOVASCULAR DISORDERS (2014)
Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations
Elisabetta Patorno et al.
DIABETOLOGIA (2014)
Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank
Andrea V. Margulis et al.
CLINICAL EPIDEMIOLOGY (2014)
Rosiglitazone and Outcomes for Patients With Diabetes Mellitus and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial
Richard G. Bach et al.
CIRCULATION (2013)
Rosiglitazone and Cardiovascular Outcomes: Is There a Clear Answer?
Hertzel C. Gerstein
CIRCULATION (2013)
Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2013)
Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis
O. J. Phung et al.
DIABETIC MEDICINE (2013)
The Cardiovascular Safety of Diabetes Drugs - Insights from the Rosiglitazone Experience
William R. Hiatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A new Comparative Effectiveness assessment strategy using the THIN database: comparison of the cardiac complications of pioglitazone and rosiglitazone
Richard Tannen et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2013)
Cardiovascular Effects of Diabetes Drugs: Emerging From the Dark Ages
Steven E. Nissen
ANNALS OF INTERNAL MEDICINE (2012)
Comparative Effectiveness of Sulfonylurea and Metformin Monotherapy on Cardiovascular Events in Type 2 Diabetes Mellitus A Cohort Study
Christianne L. Roumie et al.
ANNALS OF INTERNAL MEDICINE (2012)
Mortality in diabetes compared with previous cardiovascular disease: A gender-specific meta-analysis
C. Lee et al.
DIABETES & METABOLISM (2012)
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Joep Perk et al.
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY (2012)
Development of the RTI item bank on risk of bias and precision of observational studies
Meera Viswanathan et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2012)
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Joep Perk et al.
EUROPEAN HEART JOURNAL (2012)
Incidence of Cardiovascular Events in Which 2 Thiazolidinediones Are Used as Add-on Treatments for Type 2 Diabetes Mellitus in a Taiwanese Population
Chih-Chieh Chou et al.
CLINICAL THERAPEUTICS (2011)
IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
David R. Whiting et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2011)
Database Evaluation of the Effects of Long-Term Rosiglitazone Treatment on Cardiovascular Outcomes in Patients With Type 2 Diabetes
Ronen Loebstein et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case-control study
Henriette Thisted Horsdal et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)
Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies
Yoon Kong Loke et al.
BRITISH MEDICAL JOURNAL (2011)
Risk of Cardiovascular Events and All-Cause Mortality in Patients Treated With Thiazolidinediones in a Managed-Care Population
Debra A. Wertz et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2010)
Rapid Identification of Myocardial Infarction Risk Associated With Diabetes Medications Using Electronic Medical Records
John S. Brownstein et al.
DIABETES CARE (2010)
Cardiac safety profile of rosiglitazone A comprehensive meta-analysis of randomized clinical trials
Edoardo Mannucci et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2010)
Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone
David J. Graham et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD)
Dori Bilik et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2010)
The Thiazolidinediones Rosiglitazone and Pioglitazone and the Risk of Coronary Heart Disease: A Retrospective Cohort Study Using a US Health Insurance Database
Najat Ziyadeh et al.
CLINICAL THERAPEUTICS (2009)
Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study
Henriette T. Horsdal et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2009)
Is diabetes a coronary risk equivalent? Systematic review and meta-analysis
U. Bulugahapitiya et al.
DIABETIC MEDICINE (2009)
Thiazolidinediones and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus A Retrospective Cohort Study of over 473 000 Patients Using the National Health Insurance Database in Taiwan
Fei-Yuan Hsiao et al.
DRUG SAFETY (2009)
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Philip D. Home et al.
LANCET (2009)
Rosiglitazone and Myocardial Infarction in Patients Previously Prescribed Metformin
Colin R. Dormuth et al.
PLOS ONE (2009)
Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis
Zeina A. Habib et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2009)
Association Between Extent of Thiazolidinedione Exposure and Risk of Acute Myocardial Infarction
David D. Dore et al.
PHARMACOTHERAPY (2009)
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database
Ioanna Tzoulaki et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study
David N. Juurlink et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Pioglitazone and the Risk of Myocardial Infarction and Other Major Adverse Cardiac Events: A Meta-Analysis of Randomized, Controlled Trials
Nagapradeep Nagajothi et al.
AMERICAN JOURNAL OF THERAPEUTICS (2008)
Comparison of Cardiovascular Outcomes in Elderly Patients With Diabetes Who Initiated Rosiglitazone vs Pioglitazone Therapy
Wolfgang C. Winkelmayer et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Type of preadmission glucose-lowering treatment and prognosis among patients hospitalised with myocardial infarction: a nationwide follow-up study
H. T. Horsdal et al.
DIABETOLOGIA (2008)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007
Alexander M. Walker et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2008)
An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients
Carol E. Koro et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2008)
A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14 237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone
Alexander Cobitz et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2008)
Thiazolidinediones and cardiovascular outcomes in older patients with diabetes
Lorraine L. Lipscombe et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death
George A. Diamond et al.
ANNALS OF INTERNAL MEDICINE (2007)
A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetest
Charles M. Gerrits et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2007)
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus - A meta-analysis of randomized trials
A. Michael Lincoff et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Long-term risk of cardiovascular events with rosiglitazone - A meta-analysis
Sonal Singh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Coronary heart disease outcomes in patients receiving antidiabetic agents
Andrew T. McAfee et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Insulin sensitizing pharmacotherapy for prevention of myocardial infarction in patients with diabetes mellitus
WH Sauer et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study
SH Simpson et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2006)
Meta-analysis of observational studies in epidemiology - A proposal for reporting
DF Stroup et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
分享论文
